MENU

Can Opus Genetics (IRD) Stock Reach $13?

a clinical stage biopharmaceutical company, which engages in the research and development of oncology therapeutics

A.I.Advisor
published price charts
A.I.Advisor
Nov 11, 2026

Can Opus Genetics (IRD) Stock Reach $13?

Opus Genetics, Inc. (IRD) is a clinical-stage ophthalmic biopharmaceutical company developing gene therapies for inherited retinal diseases (IRDs, a group of rare conditions that cause progressive vision loss) and other eye disorders. The stock trades on the Nasdaq Capital Market, and its shares have been highly volatile as investors weigh a deep pipeline of early-to-late-stage candidates against a company that still generates minimal revenue and reports substantial losses. The question on many investors' minds is whether IRD can reach the $13 stock price target that reflects the average of current analyst forecasts.

Key Takeaways

  • The central target used here is $13, the rounded arithmetic mean of the verified analyst price targets reviewed, not an official published consensus.
  • The latest verified price is roughly $4.31, meaning the target implies a move of about 200% — a very large required advance.
  • Approximately 18 analysts cover the stock, with individual targets spanning a wide range from about $7 to $20, and ratings are overwhelmingly Buy or Outperform.
  • The strongest support comes from gene therapy pipeline catalysts, including a fully enrolled Phase 3 trial and near-term data readouts.
  • The biggest risks are a thin revenue base, recurring net losses, and the binary nature of clinical-stage biotech outcomes.
  • For more on this ticker's Major News, Today's Price Move, Forecast, and Earnings, explore these dedicated pages.
  • You can also explore Trending AI Robots to see how AI-driven tools scan for opportunities across thousands of stocks and ETFs.

Analyst Price Targets and Consensus View

Analyst coverage of IRD is broad but spread across a notably wide band. Targets reviewed from the second half of 2026 range from roughly $7 to $20, with the arithmetic mean landing near $13. Independent trackers report similar figures — averages around $12.70 to $13.60 depending on the analyst set — which is consistent with a rounded central target of $13. Importantly, this $13 figure is the average of individual targets, not a guarantee, and no single analyst owns it.

The dispersion explains a great deal. More cautious estimates include H.C. Wainwright at $8 and RBC Capital at $9, while more bullish calls come from Oppenheimer at $20, Citizens JMP at $17, and JonesTrading at $17. Mid-range targets include Wedbush at $13, BTIG at $12, Leerink Partners at $15, and Chardan Capital at $16. Ratings are uniformly Buy, Outperform, or Overweight among the sell-side analysts who publish price targets, with the only cautionary voices coming from quantitative rating systems rather than target-setting equity analysts.

The reasoning behind the bullish stance centers on the company's gene therapy pipeline and FDA alignment, while the low end of the range reflects the inherent execution and clinical risk of a pre-revenue biotech.

Current Market Position and Path Toward the Target

With shares trading around $4.31, reaching $13 would require a gain of roughly 200% — a very large move by any standard, even for a volatile small-cap biotech. Such a move would depend on a sustained re-rating driven by clinical data and regulatory progress rather than incremental news flow.

The company reported third-quarter 2026 license and collaboration revenue of $1.1 million and a net loss of $46.5 million, or $0.46 per share, with cash and cash equivalents of $89.0 million as of September 30, 2026. A $155 million strategic financing agreement with Oberland Capital, secured earlier in 2026, provides additional runway. The market capitalization sits around $300 million, so the path to $13 would require the pipeline's value to be substantially re-priced as programs advance.

What Could Support a Move Toward the Target

The most material catalysts are clinical. The OPGx-LCA5 registrational Phase 3 trial is fully enrolled, with dosing expected to begin in the fourth quarter of 2026. The OPGx-BEST1 Phase 1/2 program completed dosing in its high-dose cohort, with topline data anticipated in the first quarter of 2027. The FDA also cleared an investigational new drug application for OPGx-RDH12, with Phase 1/2 dosing planned. Favorable data readouts or regulatory milestones could meaningfully re-rate the shares.

Additionally, FDA approval of phentolamine ophthalmic solution 0.75% for presbyopia triggered a milestone payment from partner Viatris, offering non-dilutive upside. A broad AAV (adeno-associated virus) gene therapy platform addressing multiple retinal conditions underpins the long-term thesis.

What Could Prevent the Target From Being Reached

IRD remains a clinical-stage company with minimal revenue and steep ongoing losses. Clinical trials — particularly in gene therapy — carry binary risk, and disappointing or mixed data, safety signals, or regulatory setbacks could sharply compress the valuation. The company's negative gross margin and large net losses mean it is likely to require additional capital over time, which could dilute existing shareholders. Competition in ophthalmic gene therapy is intensifying, and the stock's own one-year gain of well over 100% already prices in substantial optimism. A broader risk-off rotation away from speculative biotech, or any financing overhang, could also weigh on the shares.

Technical Levels and Market Structure

The stock's 52-week range runs from roughly $1.22 to $5.81, reflecting extraordinary volatility. After a sharp rally, shares sit below that prior high, leaving the $5 area and the 52-week high near $5.81 as the nearest meaningful resistance zones to clear before a move toward $13 could be contemplated. On the downside, the prior multi-dollar range below $4 represents the structural support area. Given the wide price swings, the stock's trend structure remains one of high beta rather than steady accumulation.

Time Horizon and What Investors Should Monitor

Analyst price targets typically reflect a research horizon of about 12 months, and the figures cited here follow that convention, though individual analysts may differ. Investors should watch the OPGx-LCA5 Phase 3 dosing start, the OPGx-BEST1 topline data expected in the first quarter of 2027, and the OPGx-RDH12 Phase 1/2 initiation. Quarterly cash burn, financing activity, analyst target revisions, and any FDA or regulatory updates are the key near-term variables. Given the binary nature of the pipeline, data readouts — not earnings — are likely to be the dominant drivers of the stock.

AI Daily Buy/Sell Signals

For traders looking to track changing conditions in real time, Tickeron's AI Daily Buy/Sell Signals provide a systematic way to monitor sentiment shifts. The platform uses artificial intelligence to continuously scan thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on evolving market conditions, technical behavior, and AI-driven analysis. This can help traders spot opportunities, monitor existing positions, and identify changing trends more efficiently than manual screening alone. Consider reviewing these signals as one input alongside your own research when evaluating IRD.

Final Assessment

The $13 central target reflects the average of a wide analyst range — roughly $7 to $20 — rather than any single forecast. With shares near $4.31, reaching that level would require a very large advance of around 200%, a move that hinges almost entirely on successful clinical execution and favorable data readouts rather than incremental financial progress. The bullish case rests on a fully enrolled Phase 3 program, near-term catalysts, and a broad gene therapy platform, while the bearish case points to thin revenue, recurring losses, financing risk, and binary clinical outcomes. Analyst agreement on direction is strong, but the wide target dispersion underscores genuine uncertainty about magnitude. Investors should monitor the upcoming clinical milestones closely, as they are likely to determine whether $13 is reachable.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

View a ticker or compare two or three
Interact to see
Advertisement

IRD and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, IRD has been loosely correlated with ARRY. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if IRD jumps, then ARRY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IRD
1D Price
Change %
IRD100%
-2.21%
ARRY - IRD
35%
Loosely correlated
-9.67%
PRME - IRD
35%
Loosely correlated
-7.55%
DMAC - IRD
34%
Loosely correlated
+2.87%
FDMT - IRD
33%
Loosely correlated
-4.57%
SRPT - IRD
33%
Loosely correlated
-5.93%
More
Can Opus Genetics (IRD) Stock Reach $13?